Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit
Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1)
You may not be if
Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit.
Have had a thymectomy performed \< 6 months prior to the Screening Visit or have a planned thymectomy during the study
Have any active or untreated malignant thymoma
Clareo Health | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
